Biomarker Discovery Outsourcing Services Market To Reach $49.32 Billion By 2030

Biomarker Discovery Outsourcing Services Market Growth & Trends

The global biomarker discovery outsourcing services market size is expected to reach USD 49.32 billion by 2030, growing at a CAGR of 21.1% during the forecast period, according to a new report by Grand View Research, Inc. The expansion of outsourced biomarker research, attributed to the increased utilization of biomarkers in clinical trials and the accelerating level of outsourcing undertaken by pharmaceutical firms are key growth factors for this market.

Furthermore, increasing adoption of liquid biopsies is expected to drive the market growth. Liquid biopsies, which involve the analysis of biomarkers in bodily fluids like blood, urine, and cerebrospinal fluid, offer several advantages over traditional tissue biopsies, such as being less invasive and providing real-time information. As a result, the adoption of liquid biopsies has been growing rapidly, and this trend directly impacts the demand for biomarker discovery outsourcing services.

Advancements in omics technologies are expected to drive market growth in the coming years. Progress in genomics, proteomics, metabolomics, and other omics technologies has enabled the identification of novel biomarkers.Integrating data from many omics disciplines can often be advantageous for biomarker identification. This all-encompassing approach enables a more thorough comprehension of complex disorders and can result in identifying reliable, multidimensional biomarkers.Outsourcing services specializing in multi-omics data integration offer valuable expertise in this area.

An increase in drug development and clinical trials is a major contributing factor to the market growth. Biomarkers play a crucial role in drug development, helping pharmaceutical companies identify suitable drug targets, streamline clinical trial processes, and select patient populations for trials.As of 2023, the global clinical trial landscape boasts 452,604 registered trials on ClinicalTrials.gov, with 64,838 actively enrolling participants. This reflects a notable surge compared to the roughly 365,000 registered trials documented in early 2021, underscoring the robust and ongoing growth within the field of clinical research. 

 Request a free sample copy or view report summary: Biomarker Discovery Outsourcing Services Market Report

Biomarker Discovery Outsourcing Services Market Report Highlights

• Based on type, the surrogate endpoints segment held the largest share in 2022. Surrogate biomarkers can provide a more precise understanding of a drug's mechanism of action, allowing for targeted therapies and personalized medicine approaches

• The predictive biomarkers segment is expected to show significant market share in the coming years. In clinical trials, patient categorization depends on predictive biomarkers

• In the therapeutic area segment, oncology dominated the market in 2022, accounting for over 34% of the total revenue. The key factors contributing to the growth include the high incidence of cancer, personalized medicine in oncology, and increased drug development in oncology

• The autoimmune diseases segment is expected to show significant market share in the coming years. This is attributed to the advancements in omics technologies, biomarker-driven drug development, and the introduction of emerging therapies

• Based on the discovery phase segment, biomarker identification held a major revenue share of over 28% in 2022 due to wide applications of biomarker identifications in drug discovery and development. Pharmaceutical and biotechnology companies heavily rely on biomarker identification to advance their research and development efforts

Biomarker Discovery Outsourcing Services Market Segmentation

Grand View Research has segmented the global biomarker discovery outsourcing services market based on type, therapeutic area, discovery phase, end-use, and region:

Biomarker Discovery Outsourcing Services Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Predictive biomarkers

• Prognostic biomarkers

• Safety biomarkers

• Surrogate endpoints

Biomarker Discovery Outsourcing Services Therapeutic Area Outlook (Revenue, USD Billion, 2018 - 2030)

• Oncology

• Neurology

• Cardiology

• Autoimmune Diseases

• Others

Biomarker Discovery Outsourcing Services Discovery Phase Outlook (Revenue, USD Billion, 2018 - 2030)

• Biomarker Identification

• Biomarker Validation

• Biomarker Profiling

• Biomarker Panel Development

• Biomarker Selection

Biomarker Discovery Outsourcing Services End-use Outlook (Revenue, USD Billion, 2018 - 2030)

• Pharmaceutical Companies

• Biotechnology Companies

• Others

Biomarker Discovery Outsourcing Services Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Biomarker Discovery Outsourcing Services Market

• Laboratory Corporation of America Holdings

• Charles River Laboratories

• Eurofins Scientific

• Celerion, ICON plc

• Parexel International (MA) Corporation

• Proteome Sciences

• GHO Capital

• Thermo Fisher Scientific Inc.

• Evotec